Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

148.06 -1.50 (-1.00%)
Streaming Delayed Price Updated: 9:32 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher
Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024. 
Via Benzinga
Nike Stock Jumps On Upgrade As Estimates 'Finally Look Achievable' Ahead Of Paris Olympics
Dow Jones giant Nike upgraded to buy. Estimates "finally look achievable" and the Paris Olympics should provide a boon. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Is Rallybio (RLYB) Stock Up 93% Today?
Rallybio stock is rocketing higher on Thursday with heavy trading of RLYB shares after announcing a collaboration with Johnson & Johnson. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
Assessing Johnson &amp; Johnson's Performance Against Competitors In Pharmaceuticals Industry
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
These dividends are about as safe as they come. 
Via The Motley Fool
Joby’s $3.5B Air Taxi Dream Worth Less Than Trump’s Truth Social Nightmare?
Joby Aviation stock is down more than 20% in 2024. Despite the risk involved, aggressive investors are better served buying JOBY over TMTG. 
Via InvestorPlace
Topics Government
Exposures Political
Wall Street Favorites: 3 Dividend Stocks With Strong Buy Ratings for April 2024
These three dividend kings are among the most reliable dividend stocks, and each has at least one strong buy rating. 
Via InvestorPlace
7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape
Although the market may be grumbling over certain issues, concerned investors can trust these healthcare stocks to deliver the goods. 
Via InvestorPlace
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
If You Can Only Buy One Dividend Stock in April, It Better Be One of These 3 Names
The economy is performing pretty well, investing in these top dividend stocks to buy will guarantee good profits. 
Via InvestorPlace
Topics Economy
Exposures Economy
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
Balancing Dividends and Fundamentals: The Case of JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
The company is hoping to expand, but is there enough here to attract growth investors? 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry. 
Via The Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks. 
Via The Motley Fool
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
Exposures Product Safety
Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says
Johnson & Johnson acquires Shockwave Medical, bolstering its presence in cardiovascular intervention. The move marks a strategic shift, with around $30 billion invested in MedTech over 18 months. 
Via Benzinga
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend 
Via MarketBeat
Grow Your Bottom Line As Demand Increases For These Robots
Today, I’ll explain why there’s a growing need for more robots to do surgery. I’ll also show you how to collect a reliable yield while investing in a company that’s developing new surgical robots. 
Via Talk Markets
Can a New CEO Fix Boeing?
We also talk with e.l.f. Beauty CEO Tarang Amin about how the company is succeeding. 
Via The Motley Fool
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April. 
Via InvestorPlace
SWAV Stock Alert: Shockwave Medical Lands Big Buyer in Johnson & Johnson
JNJ is building a suite of heart disease treatment devices and hopes integration can help it avoid a patent cliff. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Johnson & Johnson Makes Yet Another Multi-Billion MedTech Deal With Shockwave Medical
Johnson & Johnson to acquire Shockwave Medical for $335.00/share in cash, bolstering its cardiovascular intervention portfolio. The acquisition, expected to close by mid-2024, signifies Johnson &... 
Via Benzinga
Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion
The Dow giant will pay $335 a share for Shockwave following takeover buzz. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson to Acquire Shockwave Medical
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
From Johnson & Johnson
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.